Legal & General Group Plc increased its stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 159.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 329,953 shares of the biotechnology company's stock after purchasing an additional 202,796 shares during the quarter. Legal & General Group Plc's holdings in Grifols were worth $2,453,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. R Squared Ltd acquired a new position in Grifols during the 4th quarter valued at about $28,000. GAMMA Investing LLC grew its holdings in shares of Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after buying an additional 1,527 shares during the period. Blue Trust Inc. raised its stake in Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after buying an additional 4,970 shares during the period. Envestnet Portfolio Solutions Inc. bought a new position in Grifols during the fourth quarter worth about $77,000. Finally, Raymond James Financial Inc. acquired a new position in Grifols in the fourth quarter valued at about $91,000.
Wall Street Analysts Forecast Growth
Separately, Morgan Stanley initiated coverage on Grifols in a research report on Wednesday, February 12th. They issued an "overweight" rating for the company.
View Our Latest Stock Report on Grifols
Grifols Stock Down 0.8 %
GRFS traded down $0.06 during trading on Monday, hitting $7.15. The company had a trading volume of 967,876 shares, compared to its average volume of 1,208,715. The firm's 50-day moving average price is $7.47 and its 200 day moving average price is $7.75. The company has a market capitalization of $4.92 billion, a PE ratio of 6.11 and a beta of 0.41. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a one year low of $5.79 and a one year high of $9.96.
Grifols Company Profile
(
Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Recommended Stories
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
